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The book begins by charting the rise of the
Dutch life insurance industry and the early
debates about the necessity ofmedical selection.
Horstman shows convincingly how an advisory
role distinct from family practice emerged, due
both to the industry's desire for objective risk
assessment, and to the NMG's concern that
medical assessment by family practitioners
breached patient confidentiality. The central
sections deal with the broader implications of
insurance work for medical practice. In her
account of medical examination she shows that
company worries aboutthereliability ofdoctors'
assessments led to an increasing standardization
of the examination code and recourse to
"objective" procedures such as urine analysis.
Here she echoes the argument of Marguerite
Dupree, whose study of Scottish life
examinations pointed to a transition from
diagnosis founded uponthepatient's narrative to
dependence on scientific measurement. The
destructive effect of life work on the traditional
relationship between doctorandpatient was also
evident in the demise ofprofessional secrecy,
when the NMG resolved, in 1910, that
practitioners could informcompanies ofcause of
death. Doctors' expectations that this co-
operationwouldhavepublicbenefits, intheform
ofmortality statistics or industry sponsorship of
periodical medical examinations, went
unfulfilled. Indeed Horstman's closing sections
indict the companies for abandoning the ethical
principles they initially espoused, and for
fostering a culture in which health risk was
understood as an individual rather than a
collective responsibility.
There are two areas in which fuller
contextualization wouldbehelpful. First,despite
the importance to the analysis of the life
companies' strategicdecisions, little issaidabout
their business history. Matters such as their
membership statistics, theirrangeofpolicies and
their fluctuating profitability are consigned to
footnotes (p. 63), while the mortality and
morbidity regimes in which they operated are
dealt with only cursorily (p. 31). Second, it is
surely difficult to consider the impact of life
insurance in isolation from mutual health
insurance. Scholars estimate that by 1920 some
23 per cent of the Dutch population had
sickness cover, including, for many, medical
assistance. It would therefore be interesting to
know whether this played an equally significant
part in transforming the public role of
medicine in the Netherlands.
Martin Gorsky,
University of Wolverhampton
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Whilst the identification of progress in
medicine with the introduction of one
sophisticated piece of medical technology after
another is self-evident for many and a source of
concern for a few, there are not many historical
studies that shed much light on the processes
involved. Kirk Jeffrey's careful and detailed
work, focusing on the emergence and
deployment (largely in the USA) oftwo related
technologies, the cardiac pacemaker and the
implantable defibrillator, is one that does. The
first prototype pacemakers emerged at a time,
between the two world wars, when neither
clinical practice norknowledge ofcardiac arrest
could accommodate such a device. Nor were the
material and electrical technologies on which
suchadevicenecessarily dependedthenuptothe
job. The pacemaker that, in the late 1950s, did
begin to find a place in medical practice was
a very different device from that we now know.
It was initially conceived for emergency
resuscitation ofhospital patients suffering
ventricular standstill. The notion of an
implantable pacemaker came later, and this
device was developed, more or less
simultaneously, in many places. In each of
them collaboration between cardiac surgeons,
defining the requirements that would have to
be met, and engineers, was central. Gradually,
some of these designs succeeded in attracting
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industrial interest and the pacemaker industry
wasborn. Jeffrey's study illustrates very wellthe
process by which scientific, clinical, and
technical discussion regarding the relative
merits of one or other design is gradually
transformed into competition between
commercial products vying for shares of the
world market. When the Medicare programme
came into operation, in 1966, the overall size of
the pacemaker market grew rapidly, for most
of it was in the USA. Manufacturers prospered.
Further innovation, including the search for
new applications of the device, was then
shaped by the exigencies of the market. A
reputation for technological sophistication was
one competitive strategy, preferred by some
commercial competitors. Others placed more
weight on a reputation for reliability and the
customer-support they provided. These are the
central elements in the history of almost any
modem medical technology. A strength of
Jeffrey's book lies in its comparison of the
pacemakerwiththeimplantabledefibrillatorthat
came later. There were some similarities: the
initial response ofthe clinical community was
once more one of scepticism. What this second
storyillustratesistheeffectofthenewregulatory
climate, and the concern with cost containment,
that emerged in the 1970s, with "technology"
identified as a major culprit. By 1980,
demonstrating clinical safety and efficacy was
no longer enough. Economists had arrived
on the scene.
Machines in our hearts is more a study in the
history of technology than in the history of
medicine. Itwouldbeapityifmedicalhistorians,
or health policy analysts, were put offby the
technicalities. It is precisely thebook's attention
to the motive forces ofreputation-making and
(still more) commercial competition in shaping
these technologies, their uses and their growth,
that helps us understand something of the
fundamental quality of late-twentieth-century
American medicine. Thelastchapter, 'The 1990s
and beyond', looks to the future. Jeffrey
anticipatesthe emergenceofacardiac implant to
treat congestive heart failure (CHF): "the single
mostfrequentcauseofhospitalization inpatients
over age 65". Ifand when it comes, this will be
"an important source of future revenue growth
forthe manufacturers": probably not a matterof
major interest for historians of medicine. But
what of the demarcation of the role of the
cardiologist, for this too may change? Getting
to grips with where innovative health care
technologies come from, how they are affected
by (and affect) our expectations of medicine,
and its organization, surely obliges us to look
across the boundaries of our own scholarly
disciplines too.
Stuart Blume,
University of Amsterdam
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Medical pluralism is a term that social
historians ofmedicine have long associated
with the eighteenth century, but only very
rarely with the early twentieth. The dominating
theme here has not been continuing pluralism
but rather the rise of medical science and the
tendency of modern states and their medical
professions to establish medical monopolies.
Barbara Clow uses the example of cancer
care to analyse the construction ofmedical
authority in Canada, and she suggests that
medical culture in early-twentieth-century
North America was far more pluralistic than
often assumed.
The book centres around the careers of three
popular providers of more or less heterodox
cancercuresintheCanadianprovinceofOntario,
whose influence extended far beyond the
provincial borders. Hendry Connell was a
physicianwhodeveloped anenzymeextractthat,
he believed, dissolved cancer cells by
proteolysis. John Hett, also a doctor,
experimented with a combination ofsera that he
assumed would restore the endocrine balance of
patients and trigger an immune response to the
roguecells. Finally, ReneCaisse, atrainednurse,
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